WallStreetZenWallStreetZen

NYSE: CRL
Charles River Laboratories International Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CRL

Based on 12 analysts offering 12 month price targets for Charles River Laboratories International Inc

Min Forecast
$219.00-30.58%
Avg Forecast
$318.50+0.97%
Max Forecast
$357.00+13.17%

Should I buy or sell CRL stock?

Based on 12 analysts offering ratings for Charles River Laboratories International Inc.

Strong Buy
Strong Buy
7 analysts 58.33%
Buy
3 analysts 25%
Hold
2 analysts 16.67%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although CRL's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates CRL as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their CRL stock forecasts and price targets.

CRL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-10-13
lockedlocked$00.00+00.00%2026-09-30
lockedlocked$00.00+00.00%2026-09-28Find Out Why
lockedlocked$00.00+00.00%2026-09-25
lockedlocked$00.00+00.00%2026-09-25
Evercore ISI Group
Top 18%
83
BuyMaintains$330.00+4.61%2026-09-25
RBC Capital
Top 30%
71
BuyMaintains$322.00+2.08%2026-09-25
Barclays
Top 5%
96
Strong BuyMaintains$330.00+4.61%2026-09-25Find out why
Mizuho
Top 5%
96
HoldMaintains$295.00-6.48%2026-09-25
Baird
Top 16%
85
BuyMaintains$334.00+5.88%2026-09-25

1 of 2

Forecast return on equity

Is CRL forecast to generate an efficient return?

Company
24.42%
Industry
391.32%
Market
178.31%
CRL's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CRL forecast to generate an efficient return on assets?

Company
9.21%
Industry
14.83%
CRL is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CRL earnings per share forecast

What is CRL's earnings per share in the next 3 years based on estimates from 21 analysts?

Avg 1 year Forecast
$11.49
Avg 2 year Forecast
$12.88
Avg 3 year Forecast
$14.46

CRL revenue forecast

What is CRL's revenue in the next 3 years based on estimates from 20 analysts?

Avg 1 year Forecast
$4.0B-1.12%
Avg 2 year Forecast
$4.1B+1.38%
Avg 3 year Forecast
$4.3B+7.28%
CRL's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CRL revenue growth forecast

How is CRL forecast to perform vs Diagnostics & Research companies and vs the US market?

Company
2.15%
Industry
7.7%
Market
13.47%
CRL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CRL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CRL vs Diagnostic & Research Stocks

TickerPricePrice TargetUp/downsideConsensus
CRL$315.45$318.50+0.97%Strong Buy
ICLR$174.19$180.64+3.70%Buy
MEDP$622.43$614.44-1.28%Hold
RVTY$156.01$133.10-14.68%Buy
QGEN$48.90$44.56-8.88%Buy
View Top Diagnostic & Research Stocks

Charles River Laboratories International Stock Forecast FAQ

Is Charles River Laboratories International Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 12 Wall Street analysts covering (NYSE: CRL) stock is to Strong Buy CRL stock.

Out of 12 analysts, 7 (58.33%) are recommending CRL as a Strong Buy, 3 (25%) are recommending CRL as a Buy, 2 (16.67%) are recommending CRL as a Hold, 0 (0%) are recommending CRL as a Sell, and 0 (0%) are recommending CRL as a Strong Sell.

If you're new to stock investing, here's how to buy Charles River Laboratories International stock.

What is CRL's earnings growth forecast for 2026-2028?

(NYSE: CRL) Charles River Laboratories International's forecast annual earnings growth rate of N/A is not forecast to beat the US Diagnostics & Research industry's average forecast earnings growth rate of 18.64%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.48%.

Charles River Laboratories International's earnings in 2026 is -$238,458,000.On average, 21 Wall Street analysts forecast CRL's earnings for 2026 to be $548,357,327, with the lowest CRL earnings forecast at $515,560,722, and the highest CRL earnings forecast at $575,945,621. On average, 21 Wall Street analysts forecast CRL's earnings for 2027 to be $614,981,697, with the lowest CRL earnings forecast at $556,730,725, and the highest CRL earnings forecast at $685,520,654.

In 2028, CRL is forecast to generate $690,461,627 in earnings, with the lowest earnings forecast at $594,296,444 and the highest earnings forecast at $789,634,360.

What is CRL's revenue growth forecast for 2026-2028?

(NYSE: CRL) Charles River Laboratories International's forecast annual revenue growth rate of 2.15% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 7.7%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.47%.

Charles River Laboratories International's revenue in 2026 is $3,998,987,000.On average, 20 Wall Street analysts forecast CRL's revenue for 2026 to be $188,759,499,888, with the lowest CRL revenue forecast at $182,457,968,784, and the highest CRL revenue forecast at $198,402,752,032. On average, 20 Wall Street analysts forecast CRL's revenue for 2027 to be $193,533,387,088, with the lowest CRL revenue forecast at $184,033,351,560, and the highest CRL revenue forecast at $205,324,888,472.

In 2028, CRL is forecast to generate $204,799,760,880 in revenue, with the lowest revenue forecast at $191,719,309,952 and the highest revenue forecast at $219,407,855,712.

What is CRL's forecast return on assets (ROA) for 2026-2029?

(NYSE: CRL) forecast ROA is 9.21%, which is lower than the forecast US Diagnostics & Research industry average of 14.83%.

What is CRL's Price Target?

According to 12 Wall Street analysts that have issued a 1 year CRL price target, the average CRL price target is $318.50, with the highest CRL stock price forecast at $357.00 and the lowest CRL stock price forecast at $219.00.

On average, Wall Street analysts predict that Charles River Laboratories International's share price could reach $318.50 by Oct 13, 2027. The average Charles River Laboratories International stock price prediction forecasts a potential upside of 0.97% from the current CRL share price of $315.45.

What is CRL's Earnings Per Share (EPS) forecast for 2026-2028?

(NYSE: CRL) Charles River Laboratories International's current Earnings Per Share (EPS) is -$4.79. On average, analysts forecast that CRL's EPS will be $11.49 for 2026, with the lowest EPS forecast at $10.80, and the highest EPS forecast at $12.06. On average, analysts forecast that CRL's EPS will be $12.88 for 2027, with the lowest EPS forecast at $11.66, and the highest EPS forecast at $14.36. In 2028, CRL's EPS is forecast to hit $14.46 (min: $12.45, max: $16.54).

What is CRL's forecast return on equity (ROE) for 2026-2029?

(NYSE: CRL) forecast ROE is 24.42%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.